The evolving role of PARP inhibitors in advanced ovarian cancer
, , , , , oraz
09 sie 2021
O artykule
Kategoria artykułu: Research Article
Data publikacji: 09 sie 2021
Zakres stron: 82 - 104
Otrzymano: 02 sty 2021
Przyjęty: 18 lut 2021
DOI: https://doi.org/10.2478/fco-2021-0002
Słowa kluczowe
© 2021 Sofia Levva et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Levva, Sofia
Oncology Department, Bioclinic Private HospitalThessaloniki, Greece
Skolariki, Aglaia
Department of Medical Oncology, Papageorgiou General HospitalThessaloniki, Greece
Sogka, Eleni
Department of Medical Oncology, Papageorgiou General HospitalThessaloniki, Greece
Bokas, Alexandros
1st Department of Medical Oncology, Theagenion HospitalThessaloniki, Greece
Assi, Avraam
2nd Department of Medical Oncology, Henry Dunant Hospital CenterAthens, Greece
Pispirigou, Marianna K.
Division of Oncology, Department of Internal Medicine, University Hospital of PatrasGreece
Koliou, Panagiotis
Royal Surrey NHS Foundation TrustGuildford, United Kingdom